20 research outputs found
Recommended from our members
Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.
RationaleThe monitoring of TB treatments in clinical practice and clinical trials relies on traditional sputum-based culture status indicators at specific time points. Accurate, predictive, blood-based protein markers would provide a simpler and more informative view of patient health and response to treatment.ObjectiveWe utilized sensitive, high throughput multiplexed ion mobility-mass spectrometry (IM-MS) to characterize the serum proteome of TB patients at the start of and at 8 weeks of rifamycin-based treatment. We sought to identify treatment specific signatures within patients as well as correlate the proteome signatures to various clinical markers of treatment efficacy.MethodsSerum samples were collected from 289 subjects enrolled in CDC TB Trials Consortium Study 29 at time of enrollment and at the end of the intensive phase (after 40 doses of TB treatment). Serum proteins were immunoaffinity-depleted of high abundant components, digested to peptides and analyzed for data acquisition utilizing a unique liquid chromatography IM-MS platform (LC-IM-MS). Linear mixed models were utilized to identify serum protein changes in the host response to antibiotic treatment as well as correlations with culture status end points.ResultsA total of 10,137 peptides corresponding to 872 proteins were identified, quantified, and used for statistical analysis across the longitudinal patient cohort. In response to TB treatment, 244 proteins were significantly altered. Pathway/network comparisons helped visualize the interconnected proteins, identifying up regulated (lipid transport, coagulation cascade, endopeptidase activity) and down regulated (acute phase) processes and pathways in addition to other cross regulated networks (inflammation, cell adhesion, extracellular matrix). Detection of possible lung injury serum proteins such as HPSE, significantly downregulated upon treatment. Analyses of microbiologic data over time identified a core set of serum proteins (TTHY, AFAM, CRP, RET4, SAA1, PGRP2) which change in response to treatment and also strongly correlate with culture status. A similar set of proteins at baseline were found to be predictive of week 6 and 8 culture status.ConclusionA comprehensive host serum protein dataset reflective of TB treatment effect is defined. A repeating set of serum proteins (TTHY, AFAM, CRP, RET4, SAA1, PGRP2, among others) were found to change significantly in response to treatment, to strongly correlate with culture status, and at baseline to be predictive of future culture conversion. If validated in cohorts with long term follow-up to capture failure and relapse of TB, these protein markers could be developed for monitoring of treatment in clinical trials and in patient care
Recommended from our members
Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.
RationaleThe monitoring of TB treatments in clinical practice and clinical trials relies on traditional sputum-based culture status indicators at specific time points. Accurate, predictive, blood-based protein markers would provide a simpler and more informative view of patient health and response to treatment.ObjectiveWe utilized sensitive, high throughput multiplexed ion mobility-mass spectrometry (IM-MS) to characterize the serum proteome of TB patients at the start of and at 8 weeks of rifamycin-based treatment. We sought to identify treatment specific signatures within patients as well as correlate the proteome signatures to various clinical markers of treatment efficacy.MethodsSerum samples were collected from 289 subjects enrolled in CDC TB Trials Consortium Study 29 at time of enrollment and at the end of the intensive phase (after 40 doses of TB treatment). Serum proteins were immunoaffinity-depleted of high abundant components, digested to peptides and analyzed for data acquisition utilizing a unique liquid chromatography IM-MS platform (LC-IM-MS). Linear mixed models were utilized to identify serum protein changes in the host response to antibiotic treatment as well as correlations with culture status end points.ResultsA total of 10,137 peptides corresponding to 872 proteins were identified, quantified, and used for statistical analysis across the longitudinal patient cohort. In response to TB treatment, 244 proteins were significantly altered. Pathway/network comparisons helped visualize the interconnected proteins, identifying up regulated (lipid transport, coagulation cascade, endopeptidase activity) and down regulated (acute phase) processes and pathways in addition to other cross regulated networks (inflammation, cell adhesion, extracellular matrix). Detection of possible lung injury serum proteins such as HPSE, significantly downregulated upon treatment. Analyses of microbiologic data over time identified a core set of serum proteins (TTHY, AFAM, CRP, RET4, SAA1, PGRP2) which change in response to treatment and also strongly correlate with culture status. A similar set of proteins at baseline were found to be predictive of week 6 and 8 culture status.ConclusionA comprehensive host serum protein dataset reflective of TB treatment effect is defined. A repeating set of serum proteins (TTHY, AFAM, CRP, RET4, SAA1, PGRP2, among others) were found to change significantly in response to treatment, to strongly correlate with culture status, and at baseline to be predictive of future culture conversion. If validated in cohorts with long term follow-up to capture failure and relapse of TB, these protein markers could be developed for monitoring of treatment in clinical trials and in patient care
Correlates of Physiological and Psychological Stress Among Parents of Childhood Cancer and Brain Tumor Survivors
OBJECTIVES: First, we sought to determine if parents of children with cancer or a brain tumor had greater stress compared to parents of healthy children, and to evaluate the correlates of stress among parents of children with cancer or brain tumors. Second, we sought to examine the relationship between perceived stress and symptoms of stress, and how that relationship may differ for parents of children with cancer. METHODS: In-person interviewer-assisted surveys were administered to 73 case dyads (children with cancer or a brain tumor and their parents) and 133 comparison dyads (children without health problems and their parents from a community sample). Descriptive analyses and multivariable logistic regressions were performed for case-comparison and case-only analyses to distinguish correlates of parental stress. RESULTS: Parents of children with cancer exhibited higher levels of physiological symptoms of stress than parents of healthy children. Poor sleep quality and greater social stress (negative social interactions) were significant correlates of increased levels of stress in parents of children with cancer (odds ratio 4.23, 95% confidence interval 1.15–15.60; and odds ratio 1.07, 95% confidence interval 1.00–1.14, respectively). A subset of parents reported symptoms of stress but not perceived stress, and this discordance was more pronounced among cancer caregivers. CONCLUSIONS: Implementation of screening tools that include symptoms of stress may help clinicians to comprehensively identify parents of children with cancer who are in need of additional services. Targeted stress-reduction interventions that address sleep quality and negative social interactions may mitigate the deleterious effects of caregiving, improving the psychosocial well-being of both parents and children with cancer
Deciphering ApoE Genotype-Driven Proteomic and Lipidomic Alterations in Alzheimer’s Disease Across Distinct Brain Regions
Alzheimer’s disease (AD) is a neurodegenerative
disease
with a complex etiology influenced by confounding factors such as
genetic polymorphisms, age, sex, and race. Traditionally, AD research
has not prioritized these influences, resulting in dramatically skewed
cohorts such as three times the number of Apolipoprotein E (APOE)
ε4-allele carriers in AD relative to healthy cohorts. Thus,
the resulting molecular changes in AD have previously been complicated
by the influence of apolipoprotein E disparities. To explore how apolipoprotein
E polymorphism influences AD progression, 62 post-mortem patients
consisting of 33 AD and 29 controls (Ctrl) were studied to balance
the number of ε4-allele carriers and facilitate a molecular
comparison of the apolipoprotein E genotype. Lipid and protein perturbations
were assessed across AD diagnosed brains compared to Ctrl brains,
ε4 allele carriers (APOE4+ for those carrying 1 or 2 ε4s
and APOE4– for non-ε4 carriers), and differences in ε3ε3
and ε3ε4 Ctrl brains across two brain regions (frontal
cortex (FCX) and cerebellum (CBM)). The region-specific influences
of apolipoprotein E on AD mechanisms showcased mitochondrial dysfunction
and cell proteostasis at the core of AD pathophysiology in the post-mortem
brains, indicating these two processes may be influenced by genotypic
differences and brain morphology
Deciphering ApoE Genotype-Driven Proteomic and Lipidomic Alterations in Alzheimer’s Disease Across Distinct Brain Regions
Alzheimer’s disease (AD) is a neurodegenerative
disease
with a complex etiology influenced by confounding factors such as
genetic polymorphisms, age, sex, and race. Traditionally, AD research
has not prioritized these influences, resulting in dramatically skewed
cohorts such as three times the number of Apolipoprotein E (APOE)
ε4-allele carriers in AD relative to healthy cohorts. Thus,
the resulting molecular changes in AD have previously been complicated
by the influence of apolipoprotein E disparities. To explore how apolipoprotein
E polymorphism influences AD progression, 62 post-mortem patients
consisting of 33 AD and 29 controls (Ctrl) were studied to balance
the number of ε4-allele carriers and facilitate a molecular
comparison of the apolipoprotein E genotype. Lipid and protein perturbations
were assessed across AD diagnosed brains compared to Ctrl brains,
ε4 allele carriers (APOE4+ for those carrying 1 or 2 ε4s
and APOE4– for non-ε4 carriers), and differences in ε3ε3
and ε3ε4 Ctrl brains across two brain regions (frontal
cortex (FCX) and cerebellum (CBM)). The region-specific influences
of apolipoprotein E on AD mechanisms showcased mitochondrial dysfunction
and cell proteostasis at the core of AD pathophysiology in the post-mortem
brains, indicating these two processes may be influenced by genotypic
differences and brain morphology
Discovery of a Series of 3‑Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors
We report the discovery
of a novel series of 3-cinnoline carboxamides
as highly potent and selective ataxia telangiectasia mutated (ATM)
kinase inhibitors. Optimization of this series focusing on potency
and physicochemical properties (especially permeability) led to the
identification of compound <b>21</b>, a highly potent ATM inhibitor
(ATM cell IC<sub>50</sub> 0.0028 μM) with excellent kinase selectivity
and favorable physicochemical and pharmacokinetics properties. <i>In vivo</i>, <b>21</b> in combination with irinotecan
showed tumor regression in the SW620 colorectal tumor xenograft model,
superior inhibition to irinotecan alone. Compound <b>21</b> was
selected for preclinical evaluation alongside AZD0156